206 related articles for article (PubMed ID: 29135116)
1. Serum S100B levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH.
Karonidis A; Mantzourani M; Gogas H; Tsoutsos D
J BUON; 2017; 22(5):1296-1302. PubMed ID: 29135116
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
[TBL] [Abstract][Full Text] [Related]
3. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
5. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status.
Frauchiger AL; Mangana J; Rechsteiner M; Moch H; Seifert B; Braun RP; Dummer R; Goldinger SM
Br J Dermatol; 2016 Apr; 174(4):823-30. PubMed ID: 26659191
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
8. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma.
Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E
Oncology; 1999; 56(4):338-44. PubMed ID: 10343200
[TBL] [Abstract][Full Text] [Related]
9. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
[TBL] [Abstract][Full Text] [Related]
10. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
[TBL] [Abstract][Full Text] [Related]
11. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
Schiltz PM; Dillman RO; Korse CM; Cubellis JM; Lee GJ; De Gast GC
Cancer Biother Radiopharm; 2008 Apr; 23(2):214-21. PubMed ID: 18454690
[TBL] [Abstract][Full Text] [Related]
12. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
Wagner NB; Forschner A; Leiter U; Garbe C; Eigentler TK
Br J Cancer; 2018 Aug; 119(3):339-346. PubMed ID: 29950611
[TBL] [Abstract][Full Text] [Related]
13. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
[TBL] [Abstract][Full Text] [Related]
14. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors.
Gassenmaier M; Lenders MM; Forschner A; Leiter U; Weide B; Garbe C; Eigentler TK; Wagner NB
Target Oncol; 2021 Mar; 16(2):197-205. PubMed ID: 33555543
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2003 Dec; 13(6):587-93. PubMed ID: 14646622
[TBL] [Abstract][Full Text] [Related]
16. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
Weide B; Elsässer M; Büttner P; Pflugfelder A; Leiter U; Eigentler TK; Bauer J; Witte M; Meier F; Garbe C
Br J Cancer; 2012 Jul; 107(3):422-8. PubMed ID: 22782342
[TBL] [Abstract][Full Text] [Related]
17. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H
Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898
[TBL] [Abstract][Full Text] [Related]
18. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients.
Gebhardt C; Lichtenberger R; Utikal J
J Dtsch Dermatol Ges; 2016 Feb; 14(2):158-64. PubMed ID: 26819111
[TBL] [Abstract][Full Text] [Related]
19. Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients.
Egberts F; Momkvist A; Egberts JH; Kaehler KC; Hauschild A
Anticancer Res; 2010 May; 30(5):1799-805. PubMed ID: 20592382
[TBL] [Abstract][Full Text] [Related]
20. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
